Trial Profile
A Pharmacokinetic and Pharmacodynamic Comparison of Prasugrel (LY640315) versus Clopidogrel in Subjects with Stable Atherosclerosis.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 27 May 2011
Price :
$35
*
At a glance
- Drugs Clopidogrel (Primary) ; Prasugrel (Primary) ; Aspirin
- Indications Atherosclerosis; Coronary artery disease; Embolism and thrombosis
- Focus Biomarker; Pharmacodynamics
- Sponsors Eli Lilly and Company
- 27 May 2011 New trial record